Please use this identifier to cite or link to this item:
http://hdl.handle.net/11054/749
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Preece, Patrick | * |
dc.contributor.author | Yao, Henry H. I. | * |
dc.contributor.author | Chew, Sky | * |
dc.contributor.author | Liew, Danny | * |
dc.contributor.author | McMullin, Richard | * |
dc.date.accessioned | 2015-09-25T03:30:58Z | - |
dc.date.available | 2015-09-25T03:30:58Z | - |
dc.date.issued | 2015 | en |
dc.identifier.govdoc | 00717 | en |
dc.identifier.uri | http://hdl.handle.net/11054/749 | - |
dc.description.abstract | Aims: The aim of this article is to compare the effectiveness of PSADT and tPSA as predictors of bony metastases in patients’ with prostate cancer pre-definitive treatment, and help guide clinicians with the selective ordering of bone scans (BS). Materials and methods: PSA measurements were retrospectively analysed for 330 men with prostate cancer, investigated with BS between 2009 and 2012. Exclusion criteria included previous positive BS, other malignancy, prostatectomy/radiotherapy and any prostate-specific condition or treatment initiated between the PSA levels used to calculate doubling time. PSADT (months) = log2 × dT/(log(PSA1)–log(PSA2)). Results: A total of 273 men had negative BS and 57 had positive findings of metastases. Those with positive BS had significantly (p < 0.05) faster median PSADT (4.5 vs 15.2 months) and higher median tPSA (94 vs 24.5 ng/ml). On ROC curve analysis, PSADT outperformed tPSA as a predictor of bone scan result, with area-under-the-curve of 0.85 vs 0.76 (p = 0.02). A ratio (R) of tPSA/PSADT was no better than PSADT alone (p = 0.65). Conclusions: In the absence of clinical reasons to suspect metastatic disease, it is appropriate to withhold ordering a BS for non-prostatectomy/radiotherapy patients with rising PSA levels, until the PSADT is less than 18 months. This has a sensitivity of 100.0% and a specificity of 41.0%. | en |
dc.description.provenance | Submitted by Gemma Siemensma (gemmas@bhs.org.au) on 2015-07-23T07:12:45Z No. of bitstreams: 0 | en |
dc.description.provenance | Approved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2015-09-25T03:30:58Z (GMT) No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2015-09-25T03:30:58Z (GMT). No. of bitstreams: 0 Previous issue date: 2015 | en |
dc.publisher | British Association of Urological Surgeons | en |
dc.relation.uri | http://uro.sagepub.com/content/early/2015/04/15/2051415815581097.abstract | en |
dc.title | PSA doubling time as a screening test to predict bone scan positivity. | en |
dc.type | Journal Article | * |
dc.type.specified | Article | en |
dc.bibliographicCitation.title | Journal of Clinical Urology | en |
dc.bibliographicCitation.volume | 2015 | en |
dc.bibliographicCitation.issue | April 15 | en |
dc.bibliographicCitation.stpage | 1 | en |
dc.bibliographicCitation.endpage | 6 | en |
dc.publisher.place | London, U.K. | en |
dc.subject.healththesaurus | CANCER STAGING | en |
dc.subject.healththesaurus | METASTASIS | en |
dc.subject.healththesaurus | PROSTATE CANCER | en |
dc.subject.healththesaurus | PROSTATE-SPECIFIC ANTIGEN | en |
dc.subject.healththesaurus | PROSTATIC NEOPLASMS | en |
dc.subject.healththesaurus | SCINTIGRAPHY | en |
dc.date.issuedbrowse | 2015-01-01 | en |
Appears in Collections: | Research Output |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.